Trial Information

Summary: UCD #171/GSK #104241: Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination with Vinorelbine in Advanced Solid Tumors

You have been asked to participate in this research study because you have advanced cancer that is no longer responding to treatment with standard therapy or for which no standard therapy exists.  The purpose of this study is to evaluate the side effects of and response to (staying the same or shrinking) treatment with vinorelbine (a chemotherapy drug) and lapatinib (an experimental drug).  An additional purpose is to determine the highest dose of two different schedules of lapatinib and vinorelbine that can be given without causing unmanageable side effects.  Researchers will also collect blood samples before and after treatment to evaluate whether different biological characteristics can determine who will and who will not respond to treatment with lapatinib.  Your participation in this study is expected to last for as long as your cancer is not growing and you are not having any unmanageable side effects. Your condition will be followed for 30 days after you complete treatment.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 4, 2008 at 1:47:01 PM